Woodline Partners LP Has $5.34 Million Stake in Rezolute, Inc. (NASDAQ:RZLT)

Woodline Partners LP boosted its position in shares of Rezolute, Inc. (NASDAQ:RZLT - Free Report) by 2,817.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,089,345 shares of the company's stock after acquiring an additional 1,052,002 shares during the quarter. Woodline Partners LP owned 1.88% of Rezolute worth $5,338,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. JPMorgan Chase & Co. bought a new position in shares of Rezolute in the third quarter valued at about $42,000. Alpine Global Management LLC bought a new position in shares of Rezolute in the fourth quarter valued at about $54,000. Point72 Asia Singapore Pte. Ltd. raised its position in shares of Rezolute by 48.5% in the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 19,799 shares of the company's stock valued at $97,000 after purchasing an additional 6,470 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Rezolute by 65.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 22,757 shares of the company's stock valued at $112,000 after purchasing an additional 9,000 shares during the period. Finally, Oxford Asset Management LLP bought a new position in shares of Rezolute in the fourth quarter valued at about $154,000. 82.97% of the stock is owned by institutional investors.

Rezolute Trading Up 3.2%

RZLT stock traded up $0.13 during mid-day trading on Thursday, hitting $4.08. The stock had a trading volume of 292,712 shares, compared to its average volume of 589,186. Rezolute, Inc. has a 52 week low of $2.22 and a 52 week high of $6.19. The firm has a market capitalization of $246.68 million, a P/E ratio of -3.33 and a beta of 1.01. The firm has a fifty day simple moving average of $3.31 and a 200 day simple moving average of $4.22.

Rezolute (NASDAQ:RZLT - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.05). As a group, equities analysts expect that Rezolute, Inc. will post -0.93 earnings per share for the current fiscal year.

Insider Buying and Selling at Rezolute

In related news, CEO Nevan C. Elam purchased 12,302 shares of Rezolute stock in a transaction dated Thursday, March 27th. The shares were bought at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the purchase, the chief executive officer now owns 224,119 shares in the company, valued at approximately $638,739.15. This trade represents a 5.81% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daron Evans purchased 10,000 shares of Rezolute stock in a transaction dated Wednesday, March 26th. The stock was bought at an average price of $2.89 per share, for a total transaction of $28,900.00. Following the completion of the purchase, the chief financial officer now owns 237,900 shares in the company, valued at $687,531. This represents a 4.39% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 29,060 shares of company stock valued at $83,694 in the last ninety days. 18.39% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. JMP Securities increased their price objective on shares of Rezolute from $8.00 to $9.00 and gave the company a "market outperform" rating in a research report on Thursday, February 13th. Guggenheim reaffirmed a "buy" rating on shares of Rezolute in a research report on Monday, February 10th. HC Wainwright reaffirmed a "buy" rating and set a $14.00 price target on shares of Rezolute in a research report on Monday, April 28th. Craig Hallum raised shares of Rezolute to a "strong-buy" rating in a research report on Tuesday, February 4th. Finally, Wall Street Zen lowered shares of Rezolute from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Rezolute presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.14.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.